Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Minimal Change Disease (MCD), accounts for 10–15% of primary nephrotic syndrome cases in adults. Limited studies have examined its clinical characteristics, treatment outcomes, and relapse factors in adults, particularly in low-income countries like Ethiopia. This study aimed to assess the treatment outcomes, and factors associated with relapse among adult patients with MCD at St. Paul’s Hospital Millennium Medical College in Addis Ababa, Ethiopia.
A retrospective cross-sectional review was conducted on 36 biopsy-proven adult MCD patients treated at SPHMMC between 2022 and 2024. Clinical, laboratory, and treatment data were extracted from medical records and hospital registries. Descriptive statistics summarized patient characteristics, while chi-square and independent t-tests were used to analyze associations between clinical variables and relapse, with significance set at p < 0.05.
The mean age of participants was 26.2 ± 7.1 years, with equal sex distribution . The mean 24-hour urinary protein excretion was 4677 ± 947 mg/day, and the mean serum albumin, creatinine levels and total cholesterol were 2.75 ± 0.40 g/dL, 1.01 ± 0.36 mg/dL, and 239 ± 77 mg/dL respectively. All patients received oral prednisolone as initial therapy, and 88.9% were steroid-responsive. Steroid dependence occurred in 22.2%, while 11.1% were steroid-resistant. Rituximab achieved complete remission in 75% of steroid-dependent cases. Overall, 33.3% of patients relapsed; of these, 66.7% had frequent relapses. Younger age (mean 23 ± 5 years, p = 0.047), lower baseline albumin (2.60 ± 0.29 g/dL, p = 0.01), and higher total cholesterol (298 ± 100 mg/dL, p = 0.001) were significantly associated with relapse.
Variable
Frequency or Mean
Percentage (%) or Standard Deviation (±)
Urinary protein level, g/24h
4677
± 947
Albumin, g/dl
2.75
± 0.40
Creatinine, mg/dl
1.01
± 0.36
eGFR, ml/min/1.73m²
92
± 36
Total cholesterol, mg/dL
2.82
± 0.42
LDL
239
± 77
HDL
133
± 49
Triglyceride
190
± 78
AKI
Yes
11
30.6
No
25
69.4
Hematuria
12
33.3
24
66.7
Variables
Frequency
Percentage %
Oral Prednisolone
36
100.0%
0
0.0%
Response to initial steroid responsive
32
88.9%
4
11.1%
Initial Steroid Dependent
8
22.2%
28
77.8%
Initial Steroid Resistance
Tx options and duration of tx for steroid dependent
Cyclosporine
2
25.0%
Rituximab
6
75.0%
Cyclophosphamide
Other
Tx outcome for steroid dependent
CR
PR
Tx options and duration of tx for steroid resistance
66.7%
33.3%
Tx outcome for steroid resistance
Time to complete remission for steroid dependent estimated in weeks
Mean 7.5 Weeks
SD ± 4.2 weeks
One-third of adult MCD patients experienced relapse, with younger age, hypoalbuminemia, and hypercholesterolemia identified as key predictive factors. These findings underscore the need for close monitoring and early intervention in high-risk patients to minimize relapse and optimize long-term outcomes.
